Glaukos Co. (NYSE:GKOS) Short Interest Update

Glaukos Co. (NYSE:GKOS) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 3,040,000 shares, a growth of 18.3% from the December 15th total of 2,570,000 shares. Based on an average daily volume of 567,300 shares, the days-to-cover ratio is currently 5.4 days.

Analysts Set New Price Targets

A number of research firms have weighed in on GKOS. UBS Group began coverage on shares of Glaukos in a report on Friday, December 6th. They set a “buy” rating and a $182.00 target price on the stock. Stifel Nicolaus boosted their target price on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, December 31st. Truist Financial boosted their target price on shares of Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. StockNews.com raised shares of Glaukos from a “sell” rating to a “hold” rating in a report on Monday, October 21st. Finally, Wells Fargo & Company boosted their price target on shares of Glaukos from $145.00 to $153.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $147.75.

Glaukos Stock Up 0.1 %

Shares of Glaukos stock traded up $0.09 during trading on Friday, reaching $156.60. 529,055 shares of the company traded hands, compared to its average volume of 558,098. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos has a 1-year low of $83.90 and a 1-year high of $161.13. The company has a 50 day moving average price of $145.94 and a 200-day moving average price of $133.60. The firm has a market capitalization of $8.63 billion, a PE ratio of -51.85 and a beta of 1.04.

Glaukos (NYSE:GKOS) last released its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The company had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. During the same quarter in the previous year, the company earned ($0.50) EPS. Glaukos’s quarterly revenue was up 23.9% compared to the same quarter last year. As a group, equities research analysts expect that Glaukos will post -1.89 earnings per share for the current fiscal year.

Insider Activity at Glaukos

In related news, COO Joseph E. Gilliam sold 3,328 shares of Glaukos stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $149.85, for a total transaction of $498,700.80. Following the sale, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $15,310,024.65. The trade was a 3.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Gilbert H. Kliman sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total transaction of $288,020.00. Following the sale, the director now directly owns 32,336 shares in the company, valued at $4,656,707.36. The trade was a 5.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 17,603 shares of company stock valued at $2,605,678. 6.40% of the stock is owned by insiders.

Institutional Trading of Glaukos

A number of hedge funds and other institutional investors have recently bought and sold shares of GKOS. Values First Advisors Inc. bought a new stake in Glaukos during the 3rd quarter valued at $25,000. Harvest Fund Management Co. Ltd increased its stake in Glaukos by 2,263.2% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 860 shares in the last quarter. KBC Group NV increased its stake in Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 201 shares in the last quarter. Brighton Jones LLC bought a new stake in Glaukos during the 2nd quarter valued at $208,000. Finally, EWA LLC bought a new stake in shares of Glaukos in the 3rd quarter worth $209,000. Institutional investors own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.